Related by context. All words. (Click for frequent words.) 70 Phase 1a clinical 69 Phase Ib II 69 Bayer HealthCare Onyx Pharmaceuticals 69 Phase Ib clinical 69 phase IIa clinical 69 phase IIa 69 phase Ib 68 rALLy clinical trial 68 blinded randomized placebo controlled 68 Phase IIB 68 multicenter phase 68 phase IIb 68 Initiate Phase 68 NO# [002] 67 initiate multicenter 67 multicenter Phase II 67 Initiated Phase 67 Prostate AdenoCarcinoma Treatment 67 IIa clinical trials 67 MEND CABG II 67 Medidur TM FA 67 Multiple Ascending Dose 66 LUX Lung 66 Phase 1a 66 Kahalalide F 66 IMPACT IMmunotherapy 66 REVIVE Diabetes 66 BRIM2 66 IIa trial 66 pharmacokinetic PK study 66 multicentre randomized 66 Phase Ib 66 pivotal bioequivalence 65 II Clinical Trial 65 Pivotal Phase III 65 Plicera 65 Phase III multicenter 65 Exherin TM 65 Phase Ib IIa 65 dose escalation Phase 65 TMC# C# 65 initiated Phase Ib 65 Phase IIIb clinical 65 DIRECT Trial 65 ZYBRESTAT fosbretabulin 65 Phase IIIb 65 IIa clinical trial 65 PRTX 65 multicenter Phase 65 palifosfamide Zymafos TM 65 ONCONASE R 65 Quinamed 65 IIa trials 65 GLP toxicology studies 65 SUCCEED trial 65 Cloretazine ® 65 FOLOTYN ® 65 CHAMPION PCI 65 ospemifene 65 HCV SPRINT 64 Phase 1b clinical 64 randomized controlled Phase 64 CB2 selective receptor agonist 64 EXPLORE Xa 64 PANVAC VF 64 dose escalation clinical 64 APEX PD 64 Phase 2a clinical trials 64 Pivotal Phase II 64 ENDEAVOR IV 64 confirmatory Phase III 64 PFO migraine 64 randomized controlled multicenter 64 Proellex TM 64 phase IIb clinical 64 Phase 1b Clinical Trial 64 placebo controlled Phase 64 oral picoplatin 64 initiate Phase IIb 64 Phase Ib study 64 Phase 2b Clinical Trial 64 R#/MEM # 64 XL# anticancer compounds 64 Cannabinor 64 Archexin 64 next generation URAT1 64 IIa Clinical Trial 64 Phase IIa trial 64 Phase 2a trial 64 RE LY 64 phase IIIb 64 ACCLAIM II 64 lorvotuzumab mertansine 64 number NCT# ClinicalTrials.gov 63 Testosterone MDTS ® 63 Phase 2b clinical 63 NCIC CTG 63 Commences Phase 63 MKC# MKC# PP 63 confirmatory pivotal 63 Phase Ia 63 IMA# 63 initiate Phase 2b 63 oral prodrug 63 Phase 1b trial 63 Randomized Phase 63 Phase 1b clinical trials 63 torezolid phosphate 63 confirmatory clinical 63 trastuzumab DM1 T DM1 63 REG2 63 Phase IIa clinical 63 dose escalation trial 63 Phase Ib clinical trials 63 placebo controlled multicenter 63 RhuDex 63 BRIM3 63 Randomized Double blind 63 unique alkylating agent 63 Successfully Completes Phase 63 Phase IIb III 63 MEND CABG 63 Omacetaxine 63 Phase IIA 63 Dacogen injection 63 Phase 1b 63 AVN# Phase 63 Phase 2b study 63 epigenetic therapies 63 Scopus Affiliation Identifier 63 NOX E# 63 evaluating mipomersen 63 NPC 1C 63 Prospective Randomized 63 AAG geldanamycin analog 63 prospective multicentre 63 Acetavance TM intravenous acetaminophen 63 ENESTnd 63 Phase III confirmatory 63 cathepsin K inhibitor 63 Randomized Phase II 63 Glufosfamide 63 GATTEX ™ 63 recombinant PSMA vaccine 63 Trial Evaluating 63 phase Ib clinical 63 Phase III Pivotal 63 pharmacogenomic translational research 63 AERAS-#/Crucell Ad# 63 selectin antagonist 63 Phase IIb 63 GATTEX ® 63 HuMax EGFr 63 registrational Phase 63 multicenter randomized placebo controlled 63 Phase IIb trials 63 TKB# 63 novel VDA molecule 63 clinic automation LabPas 62 pralatrexate injection folate analogue 62 Phase III Clinical Trial 62 Phase 2a clinical 62 Ocrelizumab 62 non nucleoside HCV 62 ongoing Phase IIIb 62 LUMINATE 62 NABTT 62 Phase #b/#a 62 YONDELIS 62 Fx #A 62 TBC M4 62 Phase III HEAT 62 vivo preclinical 62 TACI Ig 62 generation URAT1 inhibitor 62 PRESEPT 62 Initiates Phase II 62 preclinical efficacy 62 Second Pivotal Phase 62 alvespimycin 62 ACCLAIM COPD 62 Oral NKTR 62 GAMMAGARD 62 Alocrest 62 SUTENT ® 62 multicenter randomized controlled 62 Biopharmaceuticals AG 62 Patient Enrolment 62 castrate resistant prostate cancer 62 CEQ# 62 thorough QT 62 Pivotal Phase 62 cannabinor 62 Hsp# Inhibitor 62 tramiprosate Alzhemed TM 62 Study Evaluating 62 By JENNIFER LEARN 62 RECORD1 62 Phase IIb Clinical Trial 62 recurrent glioma 62 Panzem R NCD 62 BiTE R 62 Topline Results 62 multicenter Phase III 62 HEPLISAV ™ 62 IL# PE#QQR 62 Teplizumab 62 Phase IIb trial 62 CRMD# 62 Phase IIb clinical 62 fosbretabulin 62 candidate REP# 62 elotuzumab 62 Dalbavancin 62 Phase III ADT 62 MKC# MT 62 Elagolix 62 Phase 2b trial 62 registrational trial 61 controlled multicenter Phase 61 Meets Primary Endpoint 61 tubulin inhibitor 61 HCV RESPOND 2 61 Pivotal Trial 61 Oral Calcitonin 61 Phase 2a Clinical Trial 61 HuLuc# 61 Initiates Clinical 61 clinical trial 61 Enobia 61 diarrhea predominant irritable 61 Phase III Clinical Trials 61 evaluating Actimmune 61 INSPIRE Trial Phase III 61 tezampanel NGX# 61 Initiate Phase II 61 Tezampanel 61 VEGFR2 inhibitor 61 fostamatinib 61 Completes Patient Enrollment 61 pharmacokinetic PK 61 signal detection CTSD 61 multicenter dose escalation 61 oral proteasome inhibitor 61 LUVENIQ 61 CBLC# 61 NP2 Enkephalin 61 Phase IIb Trial 61 Phase III clinical 61 placebo controlled Phase III 61 Custirsen 61 preclinical toxicology 61 Syncria albiglutide 61 IMPDH inhibitor 61 TELINTRA R 61 PNT# 61 JAK inhibitor 61 Dyloject TM 61 multicenter prospective 61 Androxal TM 61 Combination REOLYSIN R 61 Pre RELAX AHF 61 Humanized Anti 61 Phase III placebo controlled 61 Safinamide 61 EURIDIS 61 Phase #b/#a clinical 61 balsalazide tablet 61 pain palliation 61 First Patient Enrolled 61 overactive bladder AA# 61 drug pipeline TAFA# 61 Intervention Effectiveness 61 ARRY # 61 cardio renal 61 Pharmacokinetic PK 61 R vitespen 61 R roscovitine 61 Advaxis Phase 61 budesonide MMX Phase III 61 KNS # 61 Capesaris 61 evaluating tivozanib 61 GALNS 61 Zemplar Capsules 61 clinical trials Archexin 61 GetGoal Phase III 61 includes TOLAMBA TM 61 TEMSO 61 Randomised 61 RE MODEL 61 Sorafenib HCC Assessment 61 Allovectin 7 R 61 IND enabling 61 lead Aganocide compound 61 CRLX# 60 AKT inhibitor 60 dependent kinase inhibitor 60 PrevOnco 60 albiglutide 60 HQK 60 MERLIN TIMI 60 Phase IIa 60 STEALTH C 60 Panzem R 60 PREOS 60 CCX# B 60 TransVax ™ 60 HuMax CD#b 60 Universal Flu Vaccine 60 Bioral Amphotericin B 60 phase IIb III 60 Aflibercept 60 LibiGel ® 60 Phase #/#a clinical 60 Glybera R 60 registrational 60 personalized cellular immunotherapy 60 Phase 2b monotherapy 60 Clinical Study 60 Azedra 60 Initiates Phase 2b 60 Anturol TM 60 DermaVir Patch 60 Prednisporin TM 60 MEK inhibitor RDEA# 60 Clinical Trial Results 60 depsipeptide 60 Cetrorelix 60 PEG PAL 60 Hepatocellular Carcinoma 60 Surfaxin LS 60 Clinical Trial 60 double blinded placebo 60 CLARITY study 60 First Patient Dosed 60 HGS ETR2 60 Sapacitabine 60 CTA# Injection 60 PREOS R 60 Thorough QT 60 treatment naive genotype 60 EchoCRT 60 paclitaxel poliglumex 60 Testosterone MDTS R 60 Multicenter 60 Pivotal Study 60 ORAL Solo 60 ACCEDE 60 Cloretazine R VNP#M 60 antibody MAb 60 TLK# 60 IMC #B 60 trastuzumab emtansine T DM1 60 TMC# [002] 60 Clinical Antipsychotic Trials 60 designated HVTN 60 Phase IIa trials 60 KRN# 60 telomerase therapeutic 60 Afatinib 60 MAGE A3 ASCI 60 BCIRG 60 multiple ascending dose 60 dimebon latrepirdine 60 CMV vaccine 60 bavituximab monotherapy trial 60 Personalized Immunotherapy 60 Ceflatonin R 60 granted Ortec 60 Myocet 60 Trofex 60 JAK2 Inhibitor 60 Clinical Trial Investigating REOLYSIN 60 selective androgen receptor modulator 60 Daclizumab 60 HCD# [002] 60 Aryplase 60 Luramist TM 60 ORMD 60 NS5A 60 Diamyd R 60 Silodosin 60 preclinically 60 Phase lll 60 Blinatumomab 60 RE SURGE 60 huN# DM1 60 ADVANCE PD 60 ACCORD Eye 60 fidaxomicin Phase 60 Ovarian PLCO Cancer 60 Tyrima 60 Iluvien TM 60 Dose Ranging 60 INCB# [001] 60 CCR9 antagonist 60 Medidur ™ FA 60 single ascending dose 60 rotary VAD 60 orally dosed 60 LCP AtorFen 60 OncoVEX GM CSF 60 tiapamil 60 NSABP 60 Phase 2b Trial 60 ACTEMRA TM 60 Ophena TM 60 BOLDER II 60 azilsartan medoxomil 60 novel oral anticoagulant 60 Recurrent Glioblastoma 60 Phase III 60 sunitinib malate 60 TransVax TM 60 human microdosing 60 HVTN 60 PSN# [002] 60 comparing alemtuzumab 59 BLP# Liposome Vaccine 59 randomized Phase III 59 toenail onychomycosis 59 neratinib 59 Demonstrates Positive 59 Initiates Phase III 59 Alinia 59 controlled multicenter 59 Phase Ib Clinical Trial 59 Pharmacokinetic Study 59 PROVENGE ® 59 StemEx R 59 Dose Escalation Study 59 Initiates Phase 59 Romidepsin 59 GATTEX TM 59 urocortin 2 59 novel histone deacetylase 59 MVA HPV IL2 59 EGS# 59 GRNVAC1 59 TELCYTA 59 Initiates Enrollment 59 riociguat 59 Hematide ™ 59 Prodarsan 59 XL# SAR# 59 dyskinesia PD LID 59 placebo controlled clinical 59 CALGB # [002] 59 Temsirolimus 59 Phase 2a 59 Oral Fingolimod 59 ongoing Phase 1b 59 Tesetaxel 59 CYT# potent vascular disrupting 59 Rigel R# 59 PDX pralatrexate 59 Gentamicin Surgical Implant 59 IMPACT DCM 59 NSABP B 59 celgosivir 59 Randomized Controlled 59 BY WILLA J. 59 KRYSTEXXA TM pegloticase 59 Pimavanserin 59 receptor tyrosine kinase inhibitor 59 oral deforolimus 59 Fabry Disease 59 randomized multicenter 59 OvaRex R 59 ganaxolone 59 Phase 2b Study 59 CR# vcMMAE 59 brivaracetam 59 Aplidin 59 TG MV 59 oral ghrelin agonist 59 ALN TTR 59 Hematological 59 docetaxel Taxotere R 59 multicenter randomized Phase 59 Zenvia ™ 59 vosaroxin 59 Multicenter Randomized 59 bepotastine besilate nasal spray 59 pivotal Phase III 59 PROTEGE 59 ORACLE MS 59 mertansine 59 ONTARGET 59 2 inhibitor CYT# 59 budesonide foam 59 multicentre prospective 59 TASKi2 59 GOUT 59 bapineuzumab AAB 59 hypoxia activated prodrug 59 EMPOWER ™ 59 bardoxolone 59 albiglutide currently 59 Vaxfectin ® 59 Crofelemer budesonide foam 59 lorcaserin Phase 59 label multicenter Phase 59 subcutaneous Herceptin 59 RhuDex ® 59 Confirmatory Phase 59 THR beta agonist 59 orally inhaled migraine 59 OLYMPIA registry 59 Phase III TRIST 59 Randomized Double Blind Placebo 59 Phase #/#a 59 CD# CEA 59 ILLUMINATE 59 oncolytic virus therapies 59 sapacitabine CYC# 59 Tesmilifene 59 Chemophase 59 including eniluracil ADH 59 phase IIb study 59 Multicenter Phase 59 generation PNP inhibitor 59 pharmacokinetic pharmacodynamic 59 HEPLISAV TM 59 Dose Ranging Study 59 recurrent metastatic ovarian cancer 59 tanespimycin 59 MOTIVATE 59 Zenvia Phase III 59 evaluating satraplatin 59 relapsed MM 59 Sipuleucel T 59 investigational protease inhibitor 59 examining REOLYSIN 59 Therapeutic Vaccine 59 IND submission 59 entinostat 59 Arno Therapeutics 59 DEB# 59 multicentre randomized double 59 virus HCV protease inhibitor 59 PROSTVAC VF 59 Anti CD# Antibody 59 maximally tolerated dose 59 Phase III pivotal 59 Trastuzumab DM1 59 clinical trials 59 Diamyd ® 59 StemEx 59 PSMA ADC 59 PDE4 inhibitor 59 Novolimus 59 midstage clinical 59 Presents Positive 59 Luveniq 59 cGMP manufacture 59 Valtropin 59 GCP compliant 59 Qutenza TM 59 peginesatide 59 GVAX Pancreas Vaccine 59 HCV RNA polymerase 59 icatibant 59 CCR5 mAb 59 Ophena 59 oral ridaforolimus 59 nucleoside tide 59 pharmacokinetics PK 59 TBC# 59 trodusquemine 59 Teriflunomide 59 Phase III Trial 59 mecarbil 59 leading oral taxane 59 Multimeric 59 lexidronam injection 59 Phase 2b 59 blinded placebo controlled 59 induced macular edema 59 ThermoDox ® clinical 59 Androxal ® 59 3 registrational trial 59 CARE HF 59 MVax 59 PRE SURGE 59 treatment naïve genotype 59 evaluating REVLIMID 59 Randomized Phase III 59 BLA filing 59 CURRENT OASIS 7 59 randomized Phase 2b 59 Dose Escalation 59 assessing T DM1 59 histamine dihydrochloride 59 Randomized controlled 59 Phase IIa clinical trials 59 SinuNase ™ 59 VALOR trial 59 seliciclib CYC# 59 malignant mesothelioma Alfacell 59 CA9 SCAN 59 OPT CHF 59 OvaRex ® MAb 59 Phase IIb clinical trials 59 cutaneous T 59 evaluating bafetinib 59 HuMax TAC 59 Callisto initiated 59 generation rotary VAD 59 rhFVIIa 58 novel nucleoside analog 58 Cloretazine R 58 Initiate Phase III 58 double blinded randomized 58 Vaxfectin R formulated 58 Benign Prostatic Hyperplasia 58 novel therapeutic antibodies 58 kidney urologic 58 subcutaneous formulation 58 avanafil PDE5 inhibitor 58 Simulect 58 Phase IIa proof 58 SYMMETRY trial 58 ILUVIEN ® 58 HDAC Inhibitor 58 OLpur TM H2H 58 human IgG1 monoclonal 58 AVOREN 58 oral FTY# 58 Cethromycin 58 Novel Antibiotic 58 CVBT #H 58 samalizumab 58 evaluating carfilzomib 58 Chemokine 58 ritonavir boosted danoprevir 58 Matrix Phase 2b 58 refractory chronic lymphocytic 58 Japanese Encephalitis vaccine 58 HDL Selective Delipidation 58 Phase #/#a trial 58 Elotuzumab 58 masked placebo controlled 58 Randomized Evaluation 58 Tesamorelin 58 BR.# 58 Val HeFT 58 VITAL Trial 58 Clofarabine 58 DDP# 58 liposomal formulation 58 Dupuytren Contracture 58 TRANSFORMS 58 Prolongs Survival 58 PREVAIL 58 Commence Phase 58 GW# [003] 58 Phase III randomized controlled 58 EDEMA3 58 LEVADEX TM 58 PD LID 58 ASONEP 58 TASKi3 58 p# biomarker 58 forodesine 58 Evoltra ® 58 adecatumumab 58 Pafuramidine 58 acyclovir Lauriad R 58 LymphoStat B belimumab 58 oral treprostinil 58 MVA#A 58 Traficet EN 58 IND Filing 58 Medullary Thyroid Cancer 58 LibiGel Phase III 58 ABSORB clinical 58 thymalfasin 58 Tuberculosis Vaccine 58 HGS# 58 Aplidin R 58 pan HDAC inhibitor 58 Xanafide 58 Antibody Discovery 58 glufosfamide 58 phase IIb trial 58 GTC recombinant form 58 ALS #-# 58 PEGylated interferon beta 1a 58 Prodarsan R 58 Glatiramer Acetate 58 randomized multicenter trial 58 specific CCR9 antagonist 58 prospective randomized placebo 58 randomized Phase IIb 58 MAA submission 58 RAV# 58 Hedgehog Pathway Inhibitor 58 XL# XL# XL# 58 ZFP Therapeutic 58 bazedoxifene conjugated estrogens 58 Aeolus Pharmaceuticals Announces 58 Phase II 58 RSD# oral 58 TAXUS ATLAS 58 SMT C# 58 Oral Insulin 58 Phase III clinical trials 58 cMET 58 MVA MUC1 IL2 58 CALGB 58 SPL# Gel vaginal microbicide 58 Sym# 58 prucalopride 58 Pharmacodynamic 58 YONDELIS R 58 clinical pharmacology studies 58 dose pharmacokinetic 58 IIa 58 SIMPADICO 58 Talabostat 58 polymerase inhibitor 58 diabetic neuropathic pain 58 Pertuzumab 58 ExTRACT TIMI 58 RESTORE CLI trial 58 Ofatumumab 58 Valortim 58 GSK# [002] 58 eprotirome 58 Alzhemed TM 58 Bioequivalence 58 Files Investigational 58 Immunotherapeutic 58 Triapine 58 Completes Enrollment 58 Phenoptin 58 PI3K/Akt pathway inhibitor 58 rALLy 58 Intervention Effectiveness CATIE 58 HuMax CD# 58 AVERROES 58 solid tumors ZYBRESTAT 58 Phase 58 PEG SN# 58 Diamyd Medical Diamyd 58 Initiates Clinical Trial 58 6R BH4 58 Aurora Kinase 58 Onalta ™ 58 Severe Sepsis 58 unblinding 58 TRO# 58 PROVENGE sipuleucel T 58 ICON7 58 rPA anthrax vaccine 58 Tectin TM 58 LymphoStat B TM 58 PRIMO CABG2 58 Serdaxin ® 58 mGluR5 negative 58 OncoVex 58 PROSTVAC ® 58 Microbicide 58 Oral Insulin Capsule 58 Truvada tablets 58 BLOOM Behavioral modification 58 Deforolimus 58 compound INCB# 58 Ostabolin C TM 58 ADVANCE ILLUMINATE 58 teriflunomide 58 Bosutinib 58 lucinactant 58 ERYtech 58 placebo controlled dose escalation 58 Glucosamine Chondroitin Arthritis 58 Curaxin 58 Solazed TM 58 Oglemilast 58 tramiprosate ALZHEMED TM 58 Factor VIIa 58 JZP 58 Nasdaq PGNX today 58 Zoraxel 58 MIST II 58 non nucleoside inhibitor 58 Aganocide 58 Vitaxin 58 ZFP Therapeutics 58 TransVax tm 58 Guanilib 58 specified primary endpoint 58 Phase III psoriasis 58 hGH CTP Phase 58 Prostate Cancer Vaccine 58 TransVax 58 Multicentre 58 confirmatory Phase 3 58 Pralatrexate 58 oral Janus kinase 58 Pancreas Cancer Vaccine 58 formal pharmacokinetic PK 58 huC# DM4 58 ganetespib 58 CholeraGarde R 58 LE SN# 58 recurrent malignant glioma 58 CG# oncolytic virus 58 Lung Cancer Trial 58 Randomized Clinical Trials 58 HepeX B TM 58 Annamycin 58 OHR/AVR# 58 Metastatic Melanoma 58 Cutaneous T 58 AeroLEF TM 58 Max Neeman International 58 PHASE III 58 StaphVAX R 58 IgG1 antibody 58 painful diabetic neuropathy 58 pan histone deacetylase 58 CYP#A# CYP#D# 58 Inhalation Solution 58 Vaccine Adjuvant 58 Edge STudy 58 Demonstrates Sustained 58 safety tolerability pharmacokinetics 58 pharmacokinetic PK profile 58 Motesanib 58 Mipomersen 58 dosing cohort 58 vidofludimus 58 selective modulator 58 Evaluation Program CTEP 57 RGB # 57 HPTN 57 dose escalation study 57 SNT MC# 57 Phase 2a Trial 57 cilengitide 57 Allovectin 7 ® 57 Advanced Renal Cell 57 Preclinical Study 57 generation purine nucleoside 57 atacicept 57 ENDEAVOR III 57 EOquin TM phase 57 ixabepilone 57 multicenter clinical 57 RAS MAPK pathway 57 MKC# 57 Vicriviroc 57 OAB overactive bladder 57 novel peptides 57 Golimumab 57 anti botulism antibody 57 placebo controlled randomized 57 CAPACITY trials 57 Novel Inhibitor 57 Veronate R 57 NTDDS 57 relapsed refractory multiple myeloma 57 investigational humanized monoclonal antibody 57 ACRIN 57 Systemic Sclerosis 57 generation HCV protease 57 HCV Protease Inhibitor 57 Fodosine 57 Entereg TM 57 Remission Maintenance 57 data management Clintrial 57 multicenter randomized clinical 57 Chimigen TM 57 Locteron ® 57 blinded randomized 57 CONQUER OB 57 GTC recombinant human 57 CTAP# Capsules 57 PRECISE trial 57 SNT-MC#/idebenone 57 PHX# 57 targeted radiotherapeutic 57 Dr. Fahar Merchant 57 Allovectin 7 57 ulimorelin 57 Pre Exposure Prophylaxis 57 REVIVE TA 57 5 HT2A inverse 57 taxane derivative 57 ROCKET AF 57 Degarelix 57 BCX# 57 dasatinib Sprycel ® 57 viral kinetics 57 TO AVOID PREGNANCY WHILE 57 Placebo Controlled Trial 57 L BLP# 57 PLK1 SNALP 57 therapeutic monoclonal antibody 57 Eniluracil 57 PEG Interferon lambda 57 ANTEGREN 57 Prodarsan ® 57 enoximone capsules 57 metaglidasen 57 subcutaneous PRO 57 LAB CGRP 57 Carfilzomib 57 Randomized Double Blind 57 Protexia ® 57 Trandolapril 57 dose escalation phase 57 Etubics 57 visilizumab 57 afamelanotide 57 pertuzumab 57 Kinase Inhibitor 57 Chronic Heart Failure 57 Active Ulcerative Colitis 57 Clevudine 57 Patient Enrollment 57 Confirmatory 57 modified glutathione analog 57 APPRAISE 57 HDACi 57 demonstrated antitumor activity 57 EVIZON TM 57 evaluating Prochymal 57 CLL8 57 Phase III ThermoDox 57 CoAxia 57 Tanespimycin 57 Onconase 57 opioid naive 57 Systemic Delivery 57 Microplasmin 57 aldehyde dehydrogenase ALDH2 deficiency 57 orally bioavailable 57 CCX# 57 CoFactor 57 ENRICH trial 57 Clolar ® 57 somatostatin analog 57 KL4 Surfactant 57 multicenter placebo controlled 57 Phase 2b RESTORE CLI 57 H#N# VLP vaccine 57 Receives Orphan Drug Designation 57 Saforis 57 Anturol 57 velafermin 57 REMINYL ® 57 AVN# [001] 57 telaprevir VX 57 initiate multicenter Phase 57 dextromethorphan quinidine 57 REALITY Trial 57 Empatic ™ 57 oral rivaroxaban 57 UPLYSO 57 include Ischemic Paraplegia 57 FLUPAN 57 Mitral Contour System 57 axitinib 57 GERD migraine headaches 57 selective immunoproteasome inhibitor 57 ISTODAX 57 TriGrid 57 XL# XL# XL# XL# 57 Spiegelmer ® 57 PRECISE Trial 57 DAVANAT 57 Vascular Disrupting Agent 57 imetelstat GRN#L 57 PharmaPros Corporation 57 ToGA 57 VICTOR E1 57 Eluting Stent 57 Malaria Vaccine 57 ENVISION 57 MADIT 57 APTIMA HPV assay 57 sorafenib Nexavar 57 vascular disrupting agent 57 CAMMS# 57 Initiate Clinical Trial 57 Tasimelteon 57 pharmacokinetics pharmacodynamics 57 QLT Plug Delivery 57 Anthim 57 trial evaluating PRX# 57 adecatumumab MT# 57 Frozen Shoulder syndrome Adhesive 57 Lucanix 57 preclinical 57 Dasatinib